Pharmacokinetic Study of ORM-12741 in Healthy Volunteers

Healthy Volunteers Clinical Trial

Official title:

Pharmacokinetics of ORM-12741 After Intravenous and Oral Administration and Effects of Food on ORM-12741 Pharmacokinetics; An Open, Randomised, Single Dose, Single Centre, Crossover Study in Healthy Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00818740
• Other study ID #: 3098003
• Status: Completed
• Phase: Phase 1
• First received: December 22, 2008
• Last updated: October 7, 2009
• Start date: January 2009
• Est. completion date: June 2009

Study information

• Verified date: October 2009
• Source: Orion Corporation, Orion Pharma
• Contact: n/a
• Is FDA regulated: No
• Health authority: Finland: Finnish Medicines Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine pharmacokinetic parameters of ORM-12741 in healthy volunteers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: June 2009
• Est. primary completion date: June 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion criteria:

• Written informed consent (IC) obtained.

• Good general health ascertained by detailed medical history and physical examinations.

• Finnish speaking males between 18 and 45 years of age (inclusive).

• Body Mass Index (BMI) between 18-30 kg/m2 (inclusive, BMI = weight/height2).

• Weight of 55-100 kg (inclusive).

Exclusion criteria:

• A predictable poor compliance or inability to communicate well with the investigator.

• Veins unsuitable for repeated venipuncture.

• Evidence of clinically significant cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disease as judged by the investigator.

• Any condition requiring regular concomitant medication including herbal products or likely to need any concomitant treatment during the study.

• Susceptibility to severe allergic reactions.

• Intake of any medication that could affect the outcome of the study, within 2 weeks prior to the first study treatment administration or less than 5 times a half-live of the medication. Possible enzyme inducing drugs will be discussed case-by-case with the sponsor.

• Regular consumption of more than 21 units of alcohol per week (1 unit = 4 cl spirits, about 13 g of alcohol).

• Current use of nicotine-containing products more than 5 cigarettes or equivalent/day.

• Inability to refrain from using nicotine-containing products during the stay at the study centre.

• Inability to refrain from consuming caffeine-containing beverages during the stay at the study centre e.g. propensity in getting headache when refraining from caffeine-containing beverages.

• Blood donation or loss of significant amount of blood within 2 months prior to the screening visit.

• Abnormal 12-lead ECG finding of clinical relevance after 10-minute rest in supine position at the screening visit, for example:

• QTc (calculated through the Bazett's formula) > 450msec,

• PR < 120 msec or > 210 msec,

• QRS < 70 msec or > 120 msec.

• HR < 45 beats/minute or > 100 beats/minute after 10-minute rest in supine position at the screening visit.

• At the screening visit systolic blood pressure (BP) < 90 mmHg or > 140 mmHg after 10 minutes in supine position, diastolic BP < 50 mmHg or > 90 mmHg after 10 minutes in supine position.

• Any abnormal value of laboratory, vital signs, physical examination, which may in the opinion of the investigator interfere with the interpretation of the test results or cause a health risk for the subject if he takes part into the study.

• History of drug abuse or positive result in drug abuse test.

• Positive serology to human immunodeficiency virus antibodies (HIVAgAb), hepatitis C virus antibodies (HCVAb) or hepatitis B surface antigen (HBsAg).

• Any other condition that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health risk for the study subject.

• Participation in a clinical drug study within 3 months prior to the first study treatment administration of this study or earlier participation in a clinical study with ORM-12741.

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• ORM-12741
i.v., oral solution and oral capsule forms. Oral capsule given with and without food.

Locations

Country	Name	City	State
Finland	CRST	Turku

Sponsors (1)

Lead Sponsor	Collaborator
Orion Corporation, Orion Pharma

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetic variables including: Peak concentration in plasma (Cmax), Time to peak concentration in plasma (tmax), Area under the plasma concentration-time curve (AUC)		96 hours	No
Secondary	Safety variables including blood pressure (BP), heart rate (HR), electrocardiograms (ECGs), physical examination, laboratory safety variables (haematology, chemistry, serology and urinalysis) and adverse events (AEs).		throughout the study	Yes